SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rick Strange who wrote (933)6/29/1998 1:41:00 PM
From: NeuroInvestment  Read Replies (1) of 1491
 
That depends on who the partner is (and I do not know the identity). If it is a company with reps already making the allergist/GP circuit, Alrex is just one more product in the bag. With a modicum of training and distribution of samples, the launch would be quick and easy. To any degree to which the partner is not already selling to those prescribers, the upramping would be far slower, and more expensive. If the latter case is at all applicable, PARS would have to weigh how much they are being asked to pay out for upramping, against the possible later return via increased sales. NeuroInvestment (www.neuroinv.com)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News